Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it was selected by both the Scientific and Business Advisory Boards of the Epilepsy Therapy Project to present at the 2010 Epilepsy Pipeline Update Conference, an in-depth, two day forum to be held February 25-26, 2010, at the Hyatt Embarcadero Hotel in San Francisco. Charles W. Gorodetzky, M.D., Ph.D., Catalyst's Chief Medical Officer will present an overview of CPP-115, Catalyst's development stage anticonvulsant compound, as a potential treatment for a variety of epileptic conditions, including complex partial seizures and infantile spasms (West Syndrome).
"We are pleased to be invited to join such a prestigious roster of speakers," stated Dr. Gorodetzky. "With the acquisition of worldwide rights to CPP-115, Catalyst will enter the epilepsy therapy arena with a very promising drug candidate. This meeting is an ideal venue to introduce our new compound. Catalyst will present its initial development plans and explain why we believe this drug may have improved safety and efficacy characteristics compared with the current GABA aminotransferase inhibitor, Sabril®, to an audience of experts in the development and marketing of new and existing epilepsy therapies. Catalyst looks forward to introducing this new compound as well as receiving valuable comments from these experts."